DENTSPLY SIRONA (NASDAQ:XRAY)‘s stock had its “hold” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Thursday. They presently have a $68.00 price objective on the medical instruments supplier’s stock. HC Wainwright’s price objective suggests a potential upside of 3.82% from the stock’s current price.

A number of other equities research analysts have also recently commented on XRAY. Stifel Nicolaus restated a “buy” rating and issued a $66.00 price target (down from $70.00) on shares of DENTSPLY SIRONA in a report on Thursday, August 10th. UBS reiterated a “neutral” rating and set a $59.00 price objective (down from $62.00) on shares of DENTSPLY SIRONA in a report on Thursday, August 10th. BidaskClub cut shares of DENTSPLY SIRONA from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 2nd. Stephens began coverage on shares of DENTSPLY SIRONA in a report on Tuesday, November 28th. They set an “overweight” rating and a $75.00 price objective for the company. Finally, TheStreet cut shares of DENTSPLY SIRONA from a “b” rating to a “c+” rating in a report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $67.73.

DENTSPLY SIRONA (XRAY) traded down $0.11 during trading hours on Thursday, reaching $65.50. 1,214,300 shares of the company’s stock were exchanged, compared to its average volume of 1,649,966. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.32 and a quick ratio of 1.59. The firm has a market capitalization of $14,970.00, a PE ratio of 26.14, a price-to-earnings-growth ratio of 2.60 and a beta of 1.31. DENTSPLY SIRONA has a 1-year low of $52.53 and a 1-year high of $68.98.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.04. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $978.99 million. DENTSPLY SIRONA had a negative net margin of 20.33% and a positive return on equity of 7.56%. The business’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the company posted $0.66 earnings per share. research analysts forecast that DENTSPLY SIRONA will post 2.66 EPS for the current year.

In other news, CFO Nicholas W. Alexos purchased 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The shares were acquired at an average cost of $65.85 per share, for a total transaction of $3,292,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Francis J. Lunger sold 8,900 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $65.90, for a total transaction of $586,510.00. The disclosure for this sale can be found here. 1.99% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in XRAY. Bessemer Group Inc. boosted its holdings in DENTSPLY SIRONA by 4,638.6% during the third quarter. Bessemer Group Inc. now owns 1,903,596 shares of the medical instruments supplier’s stock worth $113,855,000 after purchasing an additional 1,863,424 shares during the last quarter. Alyeska Investment Group L.P. raised its position in DENTSPLY SIRONA by 223.7% in the third quarter. Alyeska Investment Group L.P. now owns 2,271,534 shares of the medical instruments supplier’s stock worth $135,860,000 after acquiring an additional 1,569,746 shares during the period. Principal Financial Group Inc. raised its position in DENTSPLY SIRONA by 22.3% in the second quarter. Principal Financial Group Inc. now owns 6,474,432 shares of the medical instruments supplier’s stock worth $419,802,000 after acquiring an additional 1,181,547 shares during the period. Jackson Square Partners LLC raised its position in DENTSPLY SIRONA by 15.6% in the third quarter. Jackson Square Partners LLC now owns 6,334,906 shares of the medical instruments supplier’s stock worth $378,890,000 after acquiring an additional 855,199 shares during the period. Finally, Parnassus Investments CA raised its position in DENTSPLY SIRONA by 62.7% in the third quarter. Parnassus Investments CA now owns 2,115,000 shares of the medical instruments supplier’s stock worth $126,498,000 after acquiring an additional 815,000 shares during the period. Institutional investors and hedge funds own 96.58% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/12/07/dentsply-sirona-xray-earns-hold-rating-from-hc-wainwright.html.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.